Associate Director, Global Regulatory Affairs
tbd Maryland UNITED STATES
Snehal brings a confluence of early discovery, innovation and scientific expertise to her current role of Associate Director and North America regulatory liaison supporting cell and gene therapies, CAR-T and microbiome at Janssen, the pharmaceutical division of Johnson & Johnson. Beyond her role in regulatory affairs, she is founder and lead of a cross-sector gene therapy workstream, and serves on Janssen’s R&D gene therapy steering committee. With a keen interest in influencing policy for Regenerative Medicine Advanced Therapies, she staffs the regulatory committee, gene therapy and genome editing groups of the Alliance for Regenerative Medicine, the Emerging Biotherapeutics group at PhRMA and the Regenerative Medicines Working Group at BIO, and is an active member of the American Society of Gene & Cell Therapy and New York Academy of Sciences. With a penchant for exploring the unexplored, she has led biology programs at both Pfizer’s Centers for Therapeutic Innovation and Johnson & Johnson’s Janssen Incubator. Snehal graduated summa cum laude with an AB-MA in Biology from Bryn Mawr College, and holds a Ph.D. in Molecular Genetics and Genomics from Washington University in St. Louis where she also completed the Cancer Biology pathway with the Siteman Cancer Center